Anti-inflammatory impact of minocycline in a mouse model of tauopathy

Frontiers in Psychiatry

Volumn 1, Issue OCT, 2010, Pages

  Garwood, Claire J ^a   Cooper, Jonathan D ^a   Hanger, Diane P ^a   Noble, Wendy ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Array; Cytokine; Immunohistochemistry; Inflammation; Minocycline; Tau

Indexed keywords

EID: 84862779609     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2010.00136     Document Type: Article

References (65)

1. Akiyama, H., Arai, T., Kondo, H., Tanno, E., Haga, C., and Ikeda, K. (2000a). Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis. Assoc. Disord. 14(Suppl. 1), S47-S53.
2. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L., Finch, C. E., Frautschy, S., Griffin, W. S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I. R., McGeer, P. L., O'Banion, M. K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F. L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., and Wyss-Coray, T. (2000b). Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
3. Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., and Davies, P. (2005). Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci. 25, 5446-5454.
4. Andorfer, C., Kress, Y., Espinoza, M., de Silva, R., Tucker, K. L., Barde, Y. A., Duff, K., and Davies, P. (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590.
5. Bauer, J., Strauss, S. Volk, B., and Berger, M. (1991). IL-6-mediated events in Alzheimer's disease pathology. Immunol. Today 12, 422.
6. Bellucci, A., Westwood, A. J., Ingram, E., Casamenti, F., Goedert, M., and Spillantini, M. G. (2004). Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol. 165, 1643-1652.
7. Buée, L., Bussiére, T., Buée-Scherrer, V., Delacourte, A., and Hof, P. R. (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130.
8. Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., and Banati, R. B. (2001). In vivo measurement of activated microglia in dementia. Lancet 358, 461-467.
9. Cameron, B., and Landreth, G. E. (2010). Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis. 37, 503-509.
10. Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., Hobbs, W., Vonsattel, J. P., Cha, J. H., and Friedlander, R. M. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797-801.
11. Choi, C., Jeong, J. H., Jang, J. S., Choi, K., Lee, J., Kwon, J., Choi, K. G., Lee, J. S., and Kang, S. W. (2008). Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology. J. Clin. Neurol. 4, 84-88.
12. Choi, Y., Kim, H. S., Shin, K. Y., Kim, E. M., Kim, M., Kim, H. S., Park, C. H., Jeong, Y. H., Yoo, J., Lee, J. P., Chang, K. A., Kim, S., and Suh, Y. H. (2007). Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology. 32, 2393-2404.
13. Cuello, A. C., Ferretti, M. T., Leon, W. C., Iulita, M. F., Melis, T., Ducatenzeiler, A., Bruno, M. A., and Canneva, F. (2010). Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener. Dis. 7, 96-98.
14. Dickson, D. W., Lee, S. C., Mattiace, L. A., Yen, S. H., and Brosnan, C. (1993). Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7, 75-83.
15. Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L., Luecke, S., Phebus, L. A., Bymaster, F. P., and Paul, S. M. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 14669-14674.
16. Duff, K., Knight, H., Refolo, L. M., Sanders, S., Yu, X., Picciano, M., Malester, B., Hutton, M., Adamson, J., Goedert, M., Burki, K., and Davies, P. (2000). Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis. 7, 87-98.
17. Familian, A., Boshuizen, R. S., Eikelenboom, P., and Veerhuis, R. (2006). Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 53, 233-240.
18. Galasko, D., and Montine, T. J. (2010). Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark. Med. 4, 27-36.
19. Gallo, J. M., and Noble, W., and Martin, T. R. (2007). RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. Cell. Mol. Life Sci. 64, 1701-1714.
20. Giulian, D., and Ingeman, J. E. (1988). Colony-stimulating factors as promoters of ameboid microglia. J. Neurosci. 8, 4707-4717.
21. Griffin, W. S., Sheng, J. G., Roberts, G. W., and Mrak, R. E. (1995). Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54, 276-281.
22. Hanger, D. P., Anderton, B. H., and Noble, W. (2009a). Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends. Mol. Med. 15, 112-119.
23. Hanger, D. P., Seereeram, A., and Noble, W. (2009b). Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease. Expert Rev. Neurother. 9, 1647-1666.
24. Hu, W. T., Chen-Plotkin, A., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M., Pickering, E., Kuhn, M., Chen, Y., McCluskey, L., Elman, L., Karlawish, J., Hurtig, H. I., Siderowf, A., Lee, V. M., Soares, H., and Trojanowski, J. Q. (2010). Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 119, 669-678.
25. Huell, M., Strauss, S., Volk, B., Berger, M., and Bauer, J. (1995). Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol. 89, 544-551.
26. Ishizuka, K., Kimura, T., Igata-yi, R., Katsuragi, S., Takamatsu, J., and Miyakawa, T. (1997). Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin. Neurosci. 51, 135-138.
27. Jin, J. J., Kim, H. D., Maxwell, J. A., Li, L., and Fukichi, K. (2008). Toll-like receptor 4-dependent upregulation of cytokines in a transgenic model of Alzheimer's disease. J. Neuroinflamm. 5, 23.
28. Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., and Laferla, F. M. (2005). Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 8843-8853.
29. Kriz, J., Nguyen, M. D., and Julien, J. P. (2002). Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10, 268-278.
30. Laske, C., Stransky, E., Hoffmann, N., Maetzler, W., Straten, G., Eschweiler, G. W., and Leyhe, T. (2010). Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. Curr. Alzheimer Res. 7, 409-414.
31. Lee, S. M., Yune, T. Y., Kim, S. J., Park, D. W., Lee, Y. K., Kim, Y. C., Oh, Y. J., Markelonis, G. J., and Oh, T. H. (2003). Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J. Neurotrauma 20, 1017-1027.
32. Mandrekar-Colucci, S., and Landreth, G. E. (2010). Microglia and inflammation in Alzheimer's disease. CNS Neurol. Disord Drug Targets 9, 156-167.
33. Mastrangelo, M. A., Sudol, K. L., Narrow, W. C., and Bowers, W. J. (2009). Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am. J. Pathol. 175, 2076-2088.
34. McGeer, P. L., Schulzer, M., and McGeer, E. G. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425-432.
35. McKee, A. C., Carreras, I., Hossain, L., Ryu, H., Klein, W. L., Oddo, S., Laferla, F. M., Jenkins, B. G., Kowall, N. W., and Dedeoglu, A. (2008). Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 1207, 225-236.
36. Nair, A., Frederick, T. J., and Miller, S. D. (2008). Astrocytes in multiple sclerosis: a product of their environment. Cell. Mol. Life Sci. 65, 2702-2720.
37. Noble, W., Garwood, C. J., Stephenson, J., Kinsey, A. M., Hanger, D. P., and Anderton, B. H. (2009a). Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 23, 739-750.
38. Noble, W., Garwood, C. J., and Hanger, D. P. (2009b). Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion 3, 78-83.
39. Noble, W., Hanger, D. P., and Gallo, J. M. (2010). Transgenic mouse models of tauopathy in drug discovery. CNS Neurol. Disord. Drug Targets 9, 403-428.
40. Ojala, J., Alafuzoff, I., Herukka, S. K., van Groen, T., Tanila H., and Pirttila, T. (2009). Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol. Aging 30, 198-209.
41. Parachikova, A., Agadjanyan, M. G., Cribbs, D. H., Blurton-Jones, M., Perreau, V., Rogers, J., Beach, T. G., and Cotman, C. W. (2007). Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging 28, 1821-1833.
42. Parachikova, A., Visilevko, V., Cribbs, D. H., Laferla, F. M., and Green, K. N. (2010). Reductions in amyloidbeta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J. Alzheimers Dis. 21, 527-542.
43. Polydoro, M., Acker, C. M., Duff, K., Castillo, P. E., and Davies, P. (2009). Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci. 29, 10741-10749.
44. Pontikis, C. C., Cella, C. V., Parihar, N., Lim, M. J., Chakrabarti, S., Mitchison, H. M., Mobley, W. C., Rezaie, P., Pearce, D. A., and Cooper, J. D. (2004). Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 1023, 231-242.
45. Pontikis, C. C., Cotman, S. L., MacDonald, M. E., and Cooper, J. D. (2005). Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease. Neurobiol. Dis. 20, 823-836.
46. Popovic, N., Schubart, A., Goetz, B. D., Zhang, S. C., Linington, C., and Duncan, I. D. (2002). Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 51, 215-223.
47. Rice, F. L., and Van der Loos, H. (1977). Development of the barrels and barrel field in the somatosensory cortex of the mouse. J. Comp. Neurol. 171, 545-560.
48. Ryu, J. K., and McLarnon, J. G. (2006). Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood- brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp. Neurol. 198, 552-557. [Epub 2006 February 9].
49. Salmina, A. B. (2009). Neuron-glia interactions as therapeutic targets in neurodegeneration. J. Alzheimers Dis. 16, 485-502.
50. Sanchez Mejia, R. O., Ona, V. O., Li, M., and Friedlander, R. M. (2001). Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48, 1393-1399.
51. Schindowski, K., Bretteville, A., Leroy, K., Begard, S., Brion, J. P., Hamdane, M., and Buee, L. (2006). Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 169, 599-616.
52. Schwab, C., Klegeris, A., and McGeer, P. L. (2009). Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim. Biophys. Acta. 1802, 889-902.
53. Seabrook, T. J., Jiang, L., Maier, M., and Lemere, C. A. (2006). Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53, 776-782.
54. Sofroniew, M. V., and Vinters, H. V. (2010). Astrocytes: biology and pathology. Acta Neuropathol. 119, 7-35.
55. Sokolova, A., Hill, M. D., Rahimi, F., Warden, L. A., Halliday, G. M., and Shepherd, C. E. (2009). Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 19, 392-398.
56. Stirling, D. P., Khodarahmi, K., Liu, J., McPhail, L. T., McBride, C. B., Steeves, J. D., Ramer, M. S., and Tetzlaff, W. (2004). Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. 24, 2182-2190.
57. Tarkowski, E., Wallin, A., Regland, B., Blennow, K., and Tarkowski, A. (2001). Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol. Scand. 103, 166-174.
58. Teng, Y. D., Choi, H., Onario, R. C., Zhu, S., Desilets, F. C., Lan, S., Woodard, E. J., Snyder, E. Y., Eichler, M. E., and Friedlander, R. M. (2004). Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl. Acad. Sci. U.S.A. 101, 3071-3076.
59. Tucker, K. L., Meyer, M., and Barde, Y. A. (2001). Neurotrophins are required for nerve growth during development. Nat. Neurosci. 4, 29-37.
60. Van Eldik, L. J., and Griffin, W. S. (1994). S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim. Biophys. Acta 1223, 398-403.
61. Wang, X., Zhu, S., Drozda, M., Zhang, W., Stavrovskaya, I. G., Cattaneo, E., Ferrante, R. J., Kristal, B. S., and Friedlander, R. M. (2003). Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 100, 10483-10487.
62. Xia, M. Q., Qin, S. X., Wu, L. J., Mackay, C. R., and Hyman, B. T. (1998). Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am. J. Pathol. 153, 31-37.
63. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., and Lee, V. M. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351.
64. Zhang, W., Narayanan, M., and Friedlander, R. M. (2003). Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 53, 267-270.
65. Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., Gullans, S., Ferrante, R. J., Przedborski, S., Kristal, B. S., and Friedlander, R. M. (2002). Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74-78.